Skip to main content
. 2023 Mar 24;13(5):463–482. doi: 10.1016/j.jpha.2023.03.006

Fig. 11.

Fig. 11

Ginsenoside Rk3 inhibits phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) signaling pathway in vivo. (A) Westerrn blotting detection of PI3K/AKT proteins of primary liver cancer mice. (B) Immunofluorescence (IF) staining of p-PI3K and p-AKT protein of primary liver cancer mice. (C) Westerrn blotting detection of PI3K/AKT proteins of HCC-LM3 subcutaneous tumor-bearing mice. (D) IF staining of p-PI3K and p-AKT protein of HCC-LM3 subcutaneous tumor-bearing mice. L-Rk3; 50 mg/kg Rk3; H-Rk3: 100 mg/kg Rk3. Data are shown as mean ± standard deviation (SD). ∗P < 0.05 compared with the HCC or control group, ∗∗P < 0.01 compared with the HCC or control group, ∗∗∗P < 0.001 compared with the hepatocellular carcinoma (HCC) or control group.